Ireland· IE-PA-EU/1/14/978/001-002
Senshio 60 mg Film-coated tablet
A ospemifene product containing ospemifene, registered in Ireland by Shionogi B.V.. The same ATC class is registered in 11 of our 19 countries.
Checked against HPRA (Ireland) on
Informational only — not a medical device.
Where it is registered
Ospemifene is registered in 11 of 19 countries.
Countries holding a registration under ATC G03XC05 (ospemifene), each read from that country’s own register.
- This record: Ireland, from HPRA (Ireland)
- 6 of them publish a price we can compare per daily dose
Ospemifene · ATC G03XC05
11 / 19 countries
- Belgiumprice
- Canada
- Czechiaprice
- Denmark
- Finlandprice
- Icelandprice
- Ireland
- Netherlands
- Polandprice
- United Kingdom
- United Statesprice
The record
At a glance
HPRA (Ireland)- Active substance
- Ospemifene
- Manufacturer
- Shionogi B.V.
- Country
- Ireland (IE)
- ATC code
- G03XC05
- ATC class
- Ospemifene
- Defined daily dose
- 60 mg, O
- Reimbursed
- Not published by this register
- Source register
- HPRA (Ireland)
- Last checked
- September 28, 2026
Packs & prices · 1
- ie_pa_numberEU/1/14/978/001-002
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Interactions
52 interactions on record for ospemifene.
Graded by severity as the source publishes them — 7 severe. Severity grades are free for everyone; mechanism and management come with Growth.
- Severity for every pair — free, no plan needed
- The source, licence and sync date on every record
- Mechanism and what to do for each pair — Growth plan
Ospemifene · interactions on record
52 records
- 7 severe
- 45 moderate
Most severe, free to view
- Tranexamic acidB02AA02severe
- FluconazoleJ02AC01severe
- CarfilzomibL01XG02severe
- CarfilzomibL01XX45severe
- Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Same medicine, other countries
Ospemifene in 11 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- CzechiaSENSHIOShionogi B.V., Amsterdam
- SpainSENSHIO 60 MG COMPRIMIDOS RECUBIERTOS CON PELICULAShionogi B.V.
- FinlandSenshioShionogi B.V.
- IcelandSenshioShionogi B.V.
- NetherlandsSenshio 60 mg filmomhulde tablettenShionogi B.V.
- PolandSenshioShionogi B.V.
- SwedenSenshio 60 mg Filmdragerad tablettShionogi B.V
- BelgiumSenshio 60 mgShionogi Europe
Authorised across Europe · EMA
The same active substance is authorised in 3 EEA countries. Names it is sold under:
- Iceland · Senshio
- Liechtenstein · Senshio
- Norway · Senshio
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of HPRA (Ireland). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/af697365-ef2b-4e43-a1c1-56f55f2be4d6 GET /v1/drugs/af697365-ef2b-4e43-a1c1-56f55f2be4d6?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"form": "Film-coated tablet",
"routes": [
"Oral use"
],
"source": "hpra",
"atc_all": [
"G03XC05"
],
"strength": null,
"pa_number": "EU/1/14/978/001-002",
"substances": [
"Ospemifene"
],
"legal_basis": "Full application (Article 8(3) of Directive No 2001/83/EC)",
"market_info": "Unknown",
"authorised_at": null,
"dispensing_status": "Product subject to prescription which may not be renewed (A)",
"registration_status": "AU",
"supply_legal_status": "Supply through pharmacies only",
"interchangeable_code": null
}See everything about ospemifene.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.